OncLive SOSS

Acute Lymphoblastic Leukemia: The Current and Future State of Care - Episode 5

Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia

February 20, 2023

Ryan D. Cassaday, MD, University of Washington/Fred Hutch, Elias Jabbour, MD, MD Anderson Cancer Center, Gary J. Schiller, MD, Armin Ghobadi, MD

Four clinicians share best practices for assessing minimal residual disease (MRD) for ALL, touching on how these practices are evolving over time.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Patient Presentation and Diagnosis in Acute Lymphoblastic Leukemia

EP. 2: Differentiating Subtypes of Acute Lymphoblastic Leukemia

EP. 3: Emergent Data Concerning Risk Factors for Acute Lymphoblastic Leukemia

EP. 4: Standard Prognoses for Pediatric and Adult Patients with Acute Lymphoblastic Leukemia

EP. 5: Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia

EP. 6: Treatment Options for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia in the Frontline Setting

EP. 7: The Evolving Treatment Paradigm for Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

EP. 8: Recently Presented Data Informing the Treatment of Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia

EP. 9: Considerations for the Treatment of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

EP. 10: CAR T-cell Therapy in Patients with R/R Acute Lymphoblastic Leukemia

EP. 11: Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia

EP. 12: Applications for Blinatumomab in Treating Patients with R/R Acute Lymphoblastic Leukemia

EP. 13: Emerging Data Supporting the use of Tisagenlecleucel in Patients with R/R Acute Lymphoblastic Leukemia

EP. 14: On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape

x